ASX Announcement – 27 October 2026 LIVER FIBROSIS RESULTS OPEN UP GLP-1 BIOMARKER OPPORTUNITY Highlights • FibrosisAssessment aims to measure fibrosis in the liver using MRI sequences without expensive hardware or invasive contrast injections • Fibrosis in the liver is a key biomarker...
Liver Fibrosis Device - EPoC Study Results
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Resonance Health Ltd has released preliminary results from its extended proof-of-concept study for its non-invasive MRI liver fibrosis device, FibrosisAssessment, which aims to measure liver fibrosis without invasive procedures or expensive hardware. The results indicate that the device's accuracy is comparable to the widely used FibroScan ultrasound device for detecting significant fibrosis. The company plans to refine the model further and seek regulatory feedback as it moves towards commercialization.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Resonance Health
- Trading Halt
- Notice of Annual General Meeting/Proxy Form
- Liver Fibrosis Device - Clinical Trial Results - Webinar
- AGM Date & Director Nomination Closing Date
- Change in Substantial Holding
Later from Resonance Health
- $6.0 Million Placement Oversubscribed
- Proposed issue of securities - RHT
- Investor Presentation Liver Fibrosis Device & Capital Raise
- Liver Fibrosis Device Webinar Presentation
- TrialsWest East-Coast Expansion - Executive Appointment
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health